XOMA Royalty Corp.

Xoma Royalty, which has recently built a businessout of acquiring struggling biotechnology companies, has secured its latest target.In announcement late Monday, Xomasaid it has agreed to pay about $4.29 per share to acquire Generation Bio, a gene therapy developer thats currently worth less than its cash holdings.The per-share acquisition price is lower than Generations $5.39 closing price on Monday. But Generations shareholders will also receive a so-called contingent value right making them eligible to receive additional payments. Among those possible payouts are a share of any cash on hand at closing, if that total exceeds $29 million; savings on a Generation office lease; a piece of future milestones from a licensing deal with Moderna; and the proceeds, if any, should Xoma sell a delivery technology Generation had been working on.Generations board of directors unanimously approved the deal.Generation raised $200 million in an initial public offering in 2020, riding a boom in new stock offerings that lifted many preclinical drug companies and gene and cell therapy developers, specifically onto Wall Street. The company went public in the hopes of advancing a type of next-generation gene therapy technology that relied on lipid nanoparticles, rather than engineered viruses, to deliver their genetic cargo.But Generation has retrenched several times since.Shares plummeted after disappointing preclinical study resultsdelayed its development timelines in 2021. Though it formed a partnership with Modernaa couple years later, it also laid off 40% of its staff and streamlined researchamid a strategic shift.In August, Generation touted data suggesting its technology could help deliver RNA medicines into T cells. But at the time, it also slashed 90% of its workforceand began a strategic review, citing the early nature of the technology and likely long road ahead. Its longtime CEO switched to board chair shortly thereafter.Generation, then, fit the profile of the type of zombie biotech Xomahas recently begun acquiring and shutting down. Since 2024, Xoma has stepped in with bids for companies such as Turnstone Biologics,Mural Oncology, HilleVax and Lava Therapeutics.In an interview earlier this year,XomaCEO Owen Hughes described this strategy as an opportunity for struggling companies to do the right thing by shareholders and return invested capital.This structure was attractive given the circumstances, wrote Jefferies analyst Farzin Haque, in a note to clients. While Generation has a diverse set of assets with strong intellectual property protection, all of its programs will require substantial work to obtain proof-of-concept in humans and get any value from an acquirer, he wrote.Xoma is also harnessing an increasingly popular acquisition tool contingent value rights to help bump up the potential total worth of its deals. '

Dec. 05, 2025 -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “Effective Date”). Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025. Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market occurred with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025. Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law. The content above comes from the network. if any infringement, please contact us to modify.

Dec. 05, 2025 -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shareholders received $2.035 in cash per share (the “Consideration”). The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 and an extraordinary general meeting of shareholders held on October 24, 2025. The Irish High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective upon delivery of the court order to the Irish Companies Registration Office. Prior to the opening of trading on December 5, 2025, all of Mural’s shares will cease trading on Nasdaq, and Mural intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended. XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). XOMA Royalty’s board of directors and XRA 5 Corp.’s (“Sub”) board of directors accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of XOMA Royalty’s board of directors and Sub’s board of directors (who have taken all reasonable care to ensure that this is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. Davy Corporate Finance UC, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance UC or for providing advice in connection with the matters referred to in this announcement. The content above comes from the network. if any infringement, please contact us to modify.